NCT00747799已完成2 期
Phase II Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Are Failure of Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Objective response rate (CR+PR)
研究概览
简要总结
This study is a phase II clinical study. Recurrence after radiotherapy patients who are failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC) were treated by cisplatin and 5-fluorouracil with Sorafenib as first-line treatment. The objective response(complete response (CR) + partial response (PR)), Disease Control Rate , safety profile, tolerability will be evaluated according to World Health Organization (WHO) criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •ECOG Performance Status of 0 or 1
- •Life expectancy of at least 12 weeks
- •Pathologically confirmed nasopharyngeal carcinoma
- •Experience of treatment failure with radiotherapy for recurrent or metastatic NPC
- •More than 3 weeks must have elapsed since previous radiotherapy
- •Biomarkers measuring including pERK, EGFR of original diagnostic paraffin-embedded tumor samples; VEGF of pre-dose and post-dose plasma samples.
- •Subjects with at least one (for RECIST) measurable lesion (Tumor lesions that are situated in a previously irradiated area could not be considered measurable)
- •Adequate bone marrow, liver and renal functions as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •Hemoglobin > 9.0 g/dl
- •Absolute neutrophil count (ANC) > 1,500/mm3
- •Platelet count > 100,000/μl
- •Total bilirubin < 1.5 times the upper limit of normal
- •ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer), Alkaline phosphatase < 4 x ULN ,PT-INR/PTT < 1.5 x upper limit of normal, Serum creatinine < 1.5 x upper limit of normal
- •Signed and dated informed consent before the start of specific protocol procedures
排除标准
- •History of cardiac disease: congestive heart failure > NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
- •History of HIV infection
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)
- •History of organ allograft the organ allograft may be allowed as protocol specific.
- •Patients with evidence or history of bleeding diatheses
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.
- •Patients unable to swallow oral medications
- •Prior use of farnesyl transferase, Raf kinase, or MEK inhibitors
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- •Prior exposure to the study drug
研究组 & 干预措施
1
Experimental
Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
干预措施: Sorafenib plus Cisplatin and 5-fluorouracil (Drug)
结局指标
主要结局
Objective response rate (CR+PR)
时间窗: January 2009 to May 2011
In the ITT analysis(n=54), the ORR reached 77.8%: one patient (1.9%) experienced CR; 41 (75.9%), PR.
次要结局
- Disease control rate(January 2009 to May 2011)
研究者
Li Zhang
Profressor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue SarcomaPleomorphic RhabdomyosarcomaStage IIB Adult Soft Tissue Sarcoma AJCC v7Stage III Adult Soft Tissue Sarcoma AJCC v7Stage IV Adult Soft Tissue Sarcoma AJCC v7NCT02050919OHSU Knight Cancer Institute20
Unknown
不适用
Combined Radiotherapy and Sorafenib in Patients With HepatomaHepatocellular CarcinomaNCT01319942China Medical University Hospital45
已完成
2 期
Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma MultiformeGlioblastoma MultiformeNCT00544817SCRI Development Innovations, LLC47
撤回
2 期
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With IrinotecanPediatric Solid TumorsNCT02747537Washington University School of Medicine
已完成
1 期
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT00712790Singapore Clinical Research Institute35